The Journey of Azithromycin

Azithromycin is a 15-membered azalide macrolide with oral bioavailability
of approximately 37%. The low bioavailability reflects both incomplete intestinal absorption and
significant hepatic first-pass extraction. Peak plasma concentrations are modest (around 0.4 µg/mL
after 500 mg oral dose) but belie the drug's extraordinary tissue concentrations. Food reduces peak
plasma concentrations but not overall AUC for the tablet formulation; the suspension should be taken
on an empty stomach. The drug's pKa (8.3) means it exists primarily as a cation at physiological pH,
which facilitates its trapping in acidic intracellular compartments (lysosomes, phagosomes). Antacids
containing aluminum and magnesium reduce peak concentrations by approximately 25% but not the overall
AUC. Intravenous azithromycin (1-2 g/day) achieves higher plasma levels but the same tissue
distribution pattern.

Azithromycin's tissue distribution is one of the most remarkable
in clinical pharmacology. Volume of distribution is 31 L/kg — an extreme value reflecting massive
sequestration in tissues, particularly phagocytic cells. Intracellular concentrations in macrophages,
neutrophils, and monocytes reach 100-1,000 times plasma concentrations because the drug is actively
transported into these cells by an unknown mechanism and trapped in the acidic environment of
phagolysosomes (ion trapping). Tissue concentrations in lung, tonsil, prostate, and cervix are
10-100 times plasma concentrations. Plasma protein binding is relatively low at 51%. The extraordinary
tissue penetration means that plasma concentrations — used to calculate PK parameters — drastically
underestimate the drug's bioavailability at the site of infection for intracellular pathogens
(Legionella, Chlamydia, Mycoplasma) and phagocyte-associated bacteria.

Azithromycin inhibits bacterial protein synthesis by binding reversibly
to the 50S large ribosomal subunit at the peptidyl transferase center near the peptide exit tunnel.
It primarily blocks the translocation step — the movement of the growing peptide chain from the A-site
to the P-site of the ribosome — though the precise binding site and mechanism differ subtly from
classic 14-membered macrolides (erythromycin, clarithromycin). At the concentrations achieved in
phagosomes (often exceeding bacterial MIC by 10-100-fold), azithromycin is bactericidal rather than
merely bacteriostatic. Beyond direct antibacterial action, azithromycin has immunomodulatory properties:
it reduces cytokine production (IL-1β, IL-6, TNF-α), stabilizes lysosomal membranes, and modulates
neutrophil apoptosis — effects exploited in long-term macrolide therapy for bronchiectasis and diffuse
panbronchiolitis.

Azithromycin is a relatively weak CYP3A4 inhibitor — less potent
than erythromycin or clarithromycin — and does not form a stable nitrosoalkane-CYP complex. It is
primarily demethylated and hydroxylated by CYP3A4 in the liver to produce approximately 10
metabolites, all pharmacologically inactive. The drug is also a substrate for P-glycoprotein (P-gp)
efflux at the intestinal wall, contributing to its limited oral bioavailability. The absence of
significant CYP3A4 inhibition means azithromycin has fewer pharmacokinetic drug interactions than
erythromycin and clarithromycin. However, azithromycin prolongs the cardiac QT interval through
hERG (cardiac IKr) potassium channel blockade, an off-target effect shared by many macrolides,
requiring caution in patients with risk factors for arrhythmia.

Azithromycin undergoes predominantly biliary excretion; approximately
50% is excreted unchanged in feces via biliary secretion. Only 4-6% is excreted unchanged in urine,
reflecting the minimal renal contribution to elimination. The plasma elimination half-life is
approximately 68 hours, but tissue half-lives are much longer — up to 10-14 days in phagocytic
cells — explaining why a 3-day course maintains therapeutic tissue concentrations for 10 days.
This kinetic profile is the pharmacokinetic rationale for short-course (Z-pack: 500 mg on day 1,
then 250 mg on days 2-5) and single-dose (1 g for chlamydia) regimens. Hepatic impairment reduces
biliary excretion and is a relative contraindication.

Azithromycin is used for community-acquired pneumonia (atypical
organisms: Legionella, Mycoplasma, Chlamydophila), acute exacerbations of chronic bronchitis,
chlamydial infections, gonorrhea (declining due to resistance), MAC (Mycobacterium avium complex)
prophylaxis in HIV, and pediatric otitis media. Macrolide resistance is mediated by 23S rRNA
methylation (erm genes, ribosomal target modification) and macrolide efflux (mef genes). QTc
prolongation — particularly dangerous with concurrent QT-prolonging drugs or electrolyte abnormalities —
led to FDA safety communications. Long-term low-dose azithromycin (250 mg 3×/week) reduces
exacerbation frequency in bronchiectasis and COPD through anti-inflammatory rather than antibacterial
mechanisms.